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Introduction
In pulmonary arterial hypertension (PAH), pulmonary artery (PA) resistance is increased due to vasoconstriction and vascular remodeling (Thompson & Lawrie, 2017) . PAH remains a fatal disease without a cure (Peacock et al., 2007; Galiè et al., 2009) . Increased resistance in the pulmonary circulation strains the right ventricle (RV), leading to right-sided heart failure and death. The NIH registry determined that, if patients are not treated, the median survival duration of PAH patients after diagnosis is 2.8 years with the 3-year survival being 48% (D'Alonzo et al., 1991) . Since then, vasodilatory drugs affecting 3 pathways (prostacyclin, endothelin and nitric oxide) have become available to treat PAH. These drugs improve the quality of lives of patients; however, their influence on survival is minimal. Even with currently available therapies, the prognosis is poor with 3-year survival being reported to be 58-75% (Benza et al., 2010; Humbert et al., 2010; Thenappan et al., 2010; Jansa et al., 2014; Olsson et al., 2014; Chung et al., 2014) .
Thus, the development of improved therapeutic strategies is warranted for the treatment of this disease.
The major function of these approved drugs is to promote vasodilation. However, since the growth of vascular cells is also critical to the elevation of vascular resistance, agents that eliminate excess vascular cells should have therapeutic potential by reducing the thickness of the pulmonary vascular walls, which has often already increased by the time patients are diagnosed (Archer & Michelakis, 2006) . In this regard, cancer chemotherapeutic drugs with abilities to kill cells may be useful in the treatment of PAH (Suzuki et al., 2007) .
We have previously shown that anti-tumor drugs including anthracyclines and proteasome inhibitors are effective at reversing PAH by reducing PA wall thickening (Ibrahim et al., 2014; Wang et al., 2016) . These agents were found to selectively cause apoptotic and JPET #239921 autophagic death of cells in the remodeled pulmonary vasculature of animals with PAH, but not in normal vessels of animals without the disease. These drugs, however, are known to cause cardiotoxicity (Bockorny et al., 2012; Gupta et al., 2012; Menna et al., 2012; Minotti et al., 2004) , which may limit use in PAH patients with a weakened heart.
To find better drugs, the present study first examined if other anti-tumor drugs are also effective at killing pulmonary vascular cells. We identified that docetaxel (DTX) is a potent drug that can kill cultured proliferating human PA smooth muscle cells (PASMCs) and PA endothelial cells (PAECs). DTX (Taxotere) is a drug that is a member of the taxane drug class, which disrupts microtubule functions, thereby inhibiting cell division (Fojo and Menefee, 2007) . DTX is clinically used for treating locally advanced or metastatic breast cancer, head and neck cancer, gastric cancer, hormone-refractory prostate cancer and non-small cell lung cancer (Gligorov and Lotz, 2004 ). The present study tested the effects of DTX on pulmonary vascular remodeling in rats with PAH. We found that DTX, not only reverses pulmonary vascular remodeling, but also remarkably repairs the failing RV.
Materials and Methods
Cell culture experiments
Human PASMCs and PAECs were purchased from ScienCell Research Laboratories (Carlsbad, CA) and Cell Applications, Inc. (San Diego, CA) and were cultured in accordance with the manufacturers' instructions in 5% CO 2 at 37°C. Experimental results were confirmed in cells from multiple donors, and by the time this study was completed, cells from eight different individuals were purchased. Cells in passages 3-7 were used. Differentiated PASMCs were generated by using the Differentiation Medium from Cell Applications in accordance with the 
Animal experiments
The present study used the SU5416/hypoxia model with pathologic features similar to those in human PAH (Ibrahim et al., 2014; Wang et al., 2016; Taraseviciene-Stewart et al., 2001; Oka et al., 2007; Abe et al., 2010) . Male Sprague-Dawley rats (~250 g; Charles River
Laboratories, Wilmington, MA) were subcutaneously injected with 20 mg/kg body weight SU5416 (TOCRIS, Minneapolis, MN), maintained in hypoxia for 3 weeks, then in normoxia.
Animals were subjected to sustained hypoxia in a chamber regulated by an OxyCycler Oxygen Profile Controller (BioSpherix, Redfield, NY) that maintains 10% O 2 with an influx of N 2 gas (Ibrahim et al., 2014; Wang et al., 2016; Park et al., 2010) .
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After pulmonary hypertension and pulmonary vascular remodeling developed, rats were then injected intraperitoneally with pharmaceutical grade DTX (5 mg/kg body weight; Sagent Pharmaceuticals, Schaumburg, IL). After 4 days, rats were injected again with DTX (5 mg/kg).
After another 4 days, rats were injected with DTX (6 mg/kg). Control animals were injected with the equal amounts of saline. Animals were placed back in normoxia for an additional 6 days before hemodynamic measurements and the lung and heart harvest (Scheme 1).
For hemodynamic measurements, rats were anesthetized with intraperitoneal injections of urethane (1.6 g/kg body weight). Animals were then intubated and mechanically ventilated with a volume-controlled Inspira Advanced Safety Ventilator (Harvard Apparatus, Holliston, MA).
Rats were maintained on a heat pad and the temperature was kept at 37°C using a TR-200
Temperature Controller connected to a rectal probe (Fine Scientific Tools, North Vancouver, Canada). After a thoracotomy, a Millar catheter (1.4 F) was inserted into the RV. RV pressure signals were recorded by using PowerLab with Chart 5 software (ADInstruments, Colorado Springs, CO). Extrapulmonary arteries (left and right main branches) and intrapulmonary arteries (first-order branch) were surgically dissected, and connective tissues were gently removed in icecold phosphate buffered saline under a dissecting microscope.
Georgetown University Animal Care and Use Committee approved all animal experiments. The investigation conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Histological measurements
Tissues were immersed in buffered 10% formalin at room temperature, and were embedded in paraffin. Paraffin-embedded tissues were cut and mounted on glass slides. Tissue JPET #239921 sections were stained with hematoxylin and eosin (H&E). Lung slides were analyzed for PA wall thickness and vessel radius. Ten to 15 vessels were analyzed per animal, and six values for thickness and two values for radius were measured for each vessel. The % wall thickness values defined as wall thickness divided by vessel radius were calculated. Tissue sections were also evaluated for smooth muscle mass by immunohistochemistry (IHC) by using the α-smooth muscle actin antibody (Abcam, Cambridge, UK), fibrosis by Masson's trichrome stain, and apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) Assay.
TUNEL Assay was performed by using the ApopTag kit (EMD Millipore, Billerica, MA) with minor modifications. Briefly, heat-induced epitope retrieval was performed by immersing the deparaffinized tissues. Slides were exposed to terminal transferase and digoxigenin-labeled dUTP, blocked, treated with HRP-conjugated anti-digoxigenin antibody and DAB chromagen, counterstained with hematoxylin and mounted with Acrymount. % Apoptotic was calculated by dividing the number of apoptotic cells by the total number of cells.
Western blotting
Equal protein amounts of samples were electrophoresed through a reducing SDS polyacrylamide gel and electroblotted onto a membrane. The membrane was blocked and incubated with antibodies for LC3B (Cell Signaling Technology, Danvers, MA), myosin-9 (MYH9), Beclin-1 (Santa Cruz Biotechnology, Dallas, TX) and p62 (Syd Labs, Inc., Malden, MA), and levels of proteins were detected by using horseradish peroxidase-linked secondary antibodies and an Enhanced Chemiluminescence System (Amersham Life Science, Arlington Heights, IL). Seventy μg tissue homogenate proteins were used for LC3B and 50 μg tissue JPET #239921 homogenate proteins were used for Beclin-1, p62 and MYH9. Twenty μg cell lysate proteins were used for LC3B and MYH9 and 15 μg cell lysate proteins were used for Beclin-1 and p62.
Immunoprecipitation
Cell lysates were incubated with Beclin-1 antibody, MYH9 antibody or normal IgG (Santa Cruz) and GammaBind G-Sepharose (Amersham) overnight at 4 o C with gentle shaking.
Samples were centrifuged, and the pellets were washed twice with ice-cold lysis buffer without Triton X-100 and boiled in Laemmli buffer for 5 min, followed by centrifugation. The supernatants were subjected to SDS polyacrylamide gel electrophoresis. Gels were either stained with Coomassie Blue or immunoblotted with MYH9 or Beclin-1 antibody.
Statistical analysis
Means and standard errors were calculated. Comparisons between two groups were analyzed by using a two-tailed Student's t test, and comparisons between > two groups were analyzed by analysis of variance (ANOVA) with a Student-Newman-Keuls post-hoc test using the GraphPad Prism (GraphPad Software, Inc., La Jolla, CA), in accordance with the Kolmogorov-Smirnov test for normality. P < 0.05 was considered to be significant.
Results
Effects of various anti-tumor drugs on pulmonary vascular cells
We have previously shown that an anthracycline cancer chemotherapeutic agent (daunorubicin) and proteasome inhibitors (MG132, bortezomib and carfilzomib) can effectively reverse pulmonary vascular remodeling, suggesting that anti-tumor drugs may be useful for the JPET #239921 treatment of PAH (Ibrahim et al., 2014; Wang et al., 2016) . To further identify candidate drugs to be used in the PAH treatment, the present study tested various anti-tumor drugs for killing cultured proliferating/synthetic human PASMCs, the phenotype relevant to cells in the remodeled pulmonary vasculature (Ibrahim et al., 2014) . Daunorubicin, bortezomib, MG132, gemcitabine and DTX were found to effectively kill PASMCs (Fig. 1A) . By contrast, methotrexate and ifosfamide were ineffective at killing proliferating PASMCs (Fig. 1A) .
Gemcitabine, but no other drugs, also caused the significant death of differentiated/contractile
PASMCs that may resemble the functional SMCs of the pulmonary vasculature, which should be preserved ( Fig. 1B) . Thus, DTX was determined to be a promising drug to be further investigated. 1D ). The efficacy of DTX to kill human PASMCs was found to be similar to another member of the taxane family, paclitaxel ( Fig. 1E ), as well as to vincristine (Fig. 1F ), another anti-tumor drug that disrupts microtubules with a different mechanism of inhibiting microtubular polymerization.
DTX also effectively caused the death of proliferating human PAECs as determined by a cell viability assay ( Fig. 2A) as well as by cell counting (Fig. 2B ). 
DTX effectively reverses pulmonary vascular remodeling
Based on these results in cultured pulmonary vascular cells, we tested the effects of DTX in an in vivo model of PAH. The injection of SU5416 into rats followed by subjecting the animals to sustained hypoxia for 3 weeks and subsequently maintaining them in normoxia resulted in the development of severe PAH and pulmonary vascular remodeling (Oka et al., 2007) .
H&E stain and IHC with the α-smooth muscle actin antibody showed that, in contrast to the normal control lung, the majority of PA walls are thickened and most of the small caliber vessels are occluded in the lung of rats with PAH. DTX-treatment of PAH animals decreased the PA medial wall thickness, reduced the expression of α-smooth muscle actin and increased the lumen area (Fig. 3A) . The quantifications of the wall thickness of pulmonary arterioles/small PAs indicated DTX completely reversed the PA wall thickening of SU5416/hypoxia-treated rats to the normal level (Fig. 3B ). The DTX treatment had no effects on normal PA in control rats, demonstrating the selectivity of DTX to remodeled pulmonary vasculatures.
The examinations of H&E-stained slides also revealed that, while some severe pulmonary vascular remodeling lesions such as concentric lamellae and plexiform lesions are present in all the rats with PAH (Fig. 4) , we observed such lesions in only 1 out of 6 PAH rats treated with DTX.
This reversal of pulmonary vascular thickening was accompanied by a reduction in right ventricular systolic pressure (RVSP) (Figs. 5A & 5B). Heart rate was not affected by the DTX treatment in either control rats or rats with PAH ( Fig. 5C ). The treatment of PAH rats with DTX reversed RV hypertrophy as revealed by calculating Fulton Index (Fig. 5D ).
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Inhibition of autophagy mediates DTX-induced cell death
Since our previous studies using other anti-tumor drugs (daunorubicin, bortezomib and carfilzomib) showed the importance of autophagic cell death (Ibrahim et al., 2014; Wang et al., 2016) , we tested if the DTX-induced death of PASMCs may be mediated by autophagy.
Surprisingly, Fig. 6A shows that, like DTX, an autophagy inhibitor (SBI-0206965) reduced the number of proliferating/synthetic PASMCs, while an apoptosis inhibitor (Z-VAD-FMK) had no effects (Fig. 6A) . Further, the results from the experiments in which cells were transfected with siRNA for various autophagy regulatory proteins showed that knocking down mediators of autophagy, Beclin-1 (Fig. 6B ) and LC3B ( Fig. 6C ), enhanced DTX-induced cell death. By contrast, knocking down p62, which is downregulated during the autophagic process, reduced DTX-induced cell death (Fig. 6D) . These results suggest that the DTX-induced death of PASMCs is dependent on the inhibition of the cell survival role of autophagy.
In contrast to previous studies, in which anthracycline and proteasome inhibitors promoted autophagy as monitored by the formation of LC3B-II and the downregulation of p62 in remodeled pulmonary vascular smooth muscle (Ibrahim et al., 2014; Wang et al., 2016) , we found that DTX reduced the LC3B-II level ( Fig. 7A ) and increased p62 expression (Fig. 7B ) in human PASMCs. In PAs from rats with PAH, DTX administration increased the p62 level (Fig.   7C ). These results revealed that, in remodeled PASMCs with the proliferating phenotype, DTX decreases the activity of autophagy.
DTX inhibits autophagy by promoting the degradation of Beclin-1
A mechanism of the DTX-induced inhibition of autophagy appears to involve the downregulation of Beclin-1 protein expression, as DTX decreases Beclin-1 protein expression in both cultured human PASMCs (Fig. 8A ) and the PAs of rats with PAH (Fig. 8B ). The beclin-1 mRNA expression as monitored by RT-PCR was not affected by the DTX treatment of cultured PASMCs (Fig. 8C) . Further, Beclin-1 ectopically expressed via adenovirus-mediated gene transfer driven by the CMV promoter was also downregulated by DTX (Fig. 8D) .
Thus, we hypothesized that DTX drives the degradation of Beclin-1 protein. Experiments using a proteasome inhibitor support this hypothesis, as the pre-treatment of PASMCs with MG132 inhibited the DTX-induced decrease of Beclin-1 protein expression (Fig. 8E) . These results demonstrated that DTX promotes the proteasome-dependent degradation of Beclin-1 that, in turn, reduces the formation of LC3B-II and enhances p62 accumulation, leading to cell death.
DTX promotes interactions of Beclin-1 with MYH9, which participate in cell death
To explore the mechanism of the DTX regulation of Beclin-1, we searched for proteins that bind to Beclin-1 in response to the DTX treatment. Human PASMCs were treated with or without DTX, cell lysates were prepared and samples were immunoprecipitated with the rabbit Beclin-1 antibody and subjected to SDS-PAGE followed by Coomassie Blue staining. We found a band between 150 and 250 kDa to be consistently higher in DTX-treated cells (Fig. 9A ). This band was not generated when immunoprecipitation was performed with normal rabbit IgG.
Mass spectrometry identified that this band contains MYH9 (non-muscle myosin heavy chain 9; Accession P35579). The immunoprecipitation of human PASMC lysates with the Beclin-1 antibody, followed by Western blotting with the MYH9 antibody also demonstrated that DTX increased the interactions between these two proteins (Fig. 9B) . Similarly, the immunoprecipitation of PA homogenates from rats treated with DTX using the MYH9 antibody followed by Western blotting with the Beclin-1 antibody also showed this DTX-mediated event JPET #239921
( Fig. 9C) .
To assess the function of MYH9 in the regulation of DTX actions on cell death, MYH9
was knocked down in proliferating/synthetic human PASMCs by using siRNA (Fig. 9D ).
Knocking down MYH9 suppressed the DTX-induced cell death (Fig. 9E) . These results support the concept that DTX promotes the death of PASMCs by inhibiting autophagy through the proteasomal degradation of Beclin-1 that is regulated by MYH9.
DTX also downregulates Beclin-1 in cancer cells
To our knowledge, the mechanism of DTX action that mediates the Beclin-1 degradation has not been reported, even in cancer cells. Thus, we tested if the mechanism found in PASMCs may also be operative in cancer cells. As shown in Fig. 10A , treating HeLa human cervical cancer cells with DTX resulted in the downregulation of Beclin-1. Further, this effect was inhibited by a proteasome inhibitor, carfilzomib. Carfilzomib alone did not affect Beclin-1 protein expression. The downregulation of Beclin-1 also occurred with another taxane drug, paclitaxel, but not by a non-taxane modulator of microtubules, vincristine (Fig. 10B) , indicating the specificity of this mechanism to taxanes.
Effects of DTX on the heart
Anti-tumor agents have the potential to exert toxicity, in particular, cardiotoxicity (Minotti et al., 2010; Albini et al., 2010) . Since PAH patients already have failing RVs, the use of anti-tumor drugs would be a great clinical concern. The H&E-staining results shown in Remarkably, Masson's trichrome stain revealed that DTX resolved the RV fibrosis that
developed in response to PAH (Fig. 11A ). The quantifications of Masson's trichrome stain indeed determined that DTX significantly reduced the extent of RV fibrosis (Fig. 11C) .
Functionally, hemodynamic measurements indicated that the contractility index of the RV improved following the DTX treatment of PAH rats (Fig. 12B) .
These results demonstrated that DTX does not exert cardiotoxicity, rather it exerts protective effects in the RV affected by PAH.
Discussion
PAH is an aggressive disease with a high mortality rate (Thenappan et al., 2007) . The progressive nature of this disease as well as the absence of a satisfactory curative treatment raise a pressing need to investigate its underlying molecular mechanisms and provide novel therapeutic regiments for those suffering from PAH. The uncontrolled intimal and medial growth of the small pulmonary arterioles in this disease is a main trigger for the dramatic increase in PA pressure that results in RV failure. Therefore, allowing pharmacologic cell death for these unnecessary proliferating cells should ameliorate the underlying pulmonary vascular remodeling and alleviate the stress to the RV.
In our previous studies (Ibrahim et al., 2014; Wang et al., 2016) , anti-tumor drugs including an anthracycline (daunorubicin) and proteasome inhibitors (MG132, bortezomib, carfilzomib) were found to effectively promote the death of pulmonary vascular cells and reverse pulmonary vascular remodeling. The actions of these drugs to reduce PA wall thickness were specific to remodeled vessels without affecting the normal pulmonary vasculature. The administration of these anti-tumor drugs alone, however, did not influence RV pressure. Rather, we found that these anti-tumor agents are capable of potentiating the ability of vasodilators to
reduce RV pressure. Thus, we proposed that these cell-killing agents could be used in combination with already utilized vasodilators to establish better therapeutic strategies for treating PAH.
However, like many cancers, since PAH patients have short survival durations, one must decide if the benefit of aggressive therapies using anti-tumor drugs outweighs various toxicities exerted by these drugs. One serious concern with treating PAH patients with anti-tumor drugs to kill excess pulmonary vascular cells is that many of these agents may also kill cardiac muscle We questioned if other anti-tumor agents might have similar efficacies, but fewer cardiac concerns. We screened different cancer chemotherapeutic agents to mediate the cell killing of proliferating human PASMCs. Our data showed that DTX, a microtubule inhibitor, had an equal cell-killing efficacy to anthracycline (daunorubicin) and proteasome inhibitors (MG132, bortezomib). Other agents, including methotrexate (an antifolate) and ifosfamide (a nitrogen mustard alkylating agent) did not show significant cell-killing abilities. Gemcitabine (a nucleoside analog) was also effective at killing proliferating PASMCs, but this was the only drug capable of killing the differentiated/contractile phenotype as well. Thus, gemcitabine likely adversely affects the functional PASMCs needed for muscle contraction and vasoregulation.
We therefore tested the effects of DTX on an in vivo model of PAH with pathogenic features similar to those in human patients. The standard schedule of DTX administration in
human cancer is 100 mg/m 2 ; this is equivalent to 20 mg/kg body weight in rats. In the present study, we administered DTX to rats a total of 16 mg/kg body weight, that is a dose less than half of the doses previously reported in in vivo cancer studies (Chan et al., 2002; Otová et al., 2006) .
Further, our cell culture experiments were conducted by using a DTX dose in the therapeutic range (Hernández-Vargas et al., 2007) .
The present study revealed that therapeutic doses of DTX reversed pulmonary vascular remodeling and killed PASMCs and PAECs. The effects of DTX to reduce vascular wall thickness were limited to the PAs of animals with PAH, while no reduction of normal vessels was noted, indicating the selectivity of this drug. In addition, DTX exhibited superior outcomes compared with other anti-tumor agents we have previously tested (Ibrahim et al., 2014; Wang et al., 2016) in that DTX reduced the RV damage caused by PAH. It is remarkable that the already existing myocyte deterioration and already developed severe fibrosis in the RV of PAH rats were replaced with the functional myocardium by the DTX treatment.
The mechanism of DTX-induced PASMC killing was also found to be different from those of anthracycline and proteasome inhibitors, which mediate autophagic cell death (Ibrahim et al., 2014; Wang et al., 2016) . We initially hypothesized that autophagy contributes to its cellkilling efficacy by DTX. Thus, we evaluated the protein expression of Beclin-1, LC3B-II and p62. Surprisingly, in contrast to anthracycline and proteasome inhibitors, DTX caused the downregulation of LC3B-II and the upregulation of p62, indicating that the autophagy mechanism is inhibited. We have further provided evidence that this inhibition of the autophagy mechanism is through the proteasome-dependent degradation of Beclin-1, which may be regulated by MYH9. Since autophagy can also serve as a programmed cell survival mediator (Baehrecke, 2005) , autophagy may be essential to maintain the survival of PASMCs, and DTX JPET #239921
Figure Legends
Scheme 1: Schematics of animal experiments. On Day 0, rats were injected subcutaneously (S.C.) with SU5416 (20 mg/kg body weight) and placed in an OxyCycler chamber to be subjected to chronic hypoxia at 10% O 2 for 3 weeks. On Day 21, rats were then placed in normoxia for 8 weeks to promote the development of pulmonary hypertension and pulmonary vascular remodeling. On Day 77, rats were then injected intraperitoneally (i.p.) with DTX (5 mg/kg body weight). After 4 days on Day 81, rats were again injected with DTX (5 mg/kg body weight). After another 4 days on Day 85, rats were injected with DTX (6 mg/kg body weight).
Animals were kept in normoxia for an additional 6 days. 
